Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514496 · ClinicalTrials.gov registry record · Phase 1
A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
A Phase 1 study of EGFR Mutation-Related Tumors, sponsored by Nalo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
- 12
- Study locations
NCT05514496 is a Phase 1 study of EGFR Mutation-Related Tumors that is active but no longer recruiting, run by Nalo Therapeutics. The registered enrollment target is 258 participants. The trial reports 12 study locations across 5 states.
The verdict
NCT05514496, a Phase 1 study of EGFR Mutation-Related Tumors, is active but no longer recruiting, sponsored by Nalo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
Conditions Studied
Interventions
- DRUG NX-019
Study Locations (12)
Other
- Seoul National University Hospital - Seoul
- Severance Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- City of Hope - Seacliff - Huntington Beach
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
Minnesota
- HealthPartners Frauenshuh Cancer Center - Saint Louis Park
- HealthPartners Cancer Center at Regions Hospital - Saint Paul
Virginia
- University Of Virginia Comprehensive Cancer Center - Charlottesville
- NEXT Virginia - Fairfax
Taipei
- National Taiwan University Cancer Center - Taipei City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514496
The ClinicalTrials.gov registry entry for NCT05514496 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nalo Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with EGFR Mutation-Related Tumors appearing as the primary indexed condition, and to 1 intervention - of which NX-019 is the first listed.
NCT05514496 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05514496 about?
NCT05514496 is a clinical study titled "A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer". This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
What is the current status of trial NCT05514496?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2022-10-05. Estimated completion is 2025-12-01.
What conditions does trial NCT05514496 study?
This clinical trial studies the following conditions: EGFR Mutation-Related Tumors.
What interventions are being tested in trial NCT05514496?
The interventions under investigation include: NX-019 (DRUG).
Who is sponsoring clinical trial NCT05514496?
This trial is sponsored by Nalo Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514496 being conducted?
This trial has 12 study locations across California, Minnesota, Virginia, Taipei. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for EGFR Mutation-Related Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.